Mar 23, 2022 / 03:15PM GMT
Paul Richard Knight - KeyBanc Capital Markets Inc., Research Division - MD & Senior Analyst
This is Paul Knight, analyst at KeyBanc on the life science market. We've had a lot of discussions over bioproduction in the life science markets over the last 1.5 days. With us today, we have Bio-Techne. David Clair will be joining us and Will Geist. You are here, you're ready to go. If you could do an intro and some opening comments, that would be great.
William A. Geist - Bio-Techne Corporation - President of Protein Sciences Segment
Yes. Thanks so much, Paul. So I'm Will Geist. I'm President of the Protein Sciences segment here at Bio-Techne. Started January 3. And kind of my purview is currently in that group, the proteomic research reagents and analytical tools. Those fit into a couple of different divisions, our Reagent Solutions Division and our Analytical Solutions Division. So really looking forward to the discussion today. And let's have at it.
Bio-Techne Corp at KeyBanc Capital Markets Life Sciences & MedTech Forum (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot